What Is Ergothioneine?
Ergothioneine (abbreviated ERGO or ET) is a naturally occurring amino acid with a distinctive sulfur-containing imidazole ring structure. First discovered in 1909 in ergot fungi, it has since been identified in a wide range of organisms — though humans cannot synthesize it and must obtain it from dietary sources.
What makes ergothioneine unusual among antioxidants is its dedicated transporter. Humans express a specific protein called OCTN1 (organic cation transporter novel type 1), encoded by the SLC22A4 gene, whose primary function appears to be absorbing and retaining ergothioneine. The existence of a dedicated transporter strongly suggests that ergothioneine plays an important biological role — the body wouldn't maintain specialized uptake machinery for a trivial molecule.
Ergothioneine accumulates in tissues with high oxidative stress exposure: red blood cells, the liver, kidneys, bone marrow, seminal fluid, and the lens of the eye. It crosses the blood-brain barrier via OCTN1, which has fueled particular interest in its potential neuroprotective effects.
The richest dietary sources are mushrooms — particularly king oyster, maitake, shiitake, and oyster mushrooms — along with some organ meats and beans. Average dietary intake in Western populations is estimated at 1–5 mg per day, though this varies substantially with mushroom consumption.
How Ergothioneine Works
A Unique Antioxidant Profile
Ergothioneine's antioxidant chemistry is distinct from more familiar antioxidants like vitamin C, vitamin E, or glutathione. Its thione (sulfur-containing) group gives it several advantageous properties:
- Exceptional stability. Unlike glutathione, which is rapidly oxidized and consumed in reactions, ergothioneine is remarkably stable under physiological conditions. It doesn't auto-oxidize in the presence of iron or copper ions — a critical advantage because these metal-catalyzed reactions generate harmful hydroxyl radicals.
- Metal chelation. Ergothioneine can bind iron and copper ions, preventing them from catalyzing Fenton reactions that produce reactive oxygen species (ROS).
- Selective reactivity. Rather than reacting indiscriminately with all free radicals, ergothioneine preferentially scavenges the most damaging species: hydroxyl radicals, hypochlorous acid, and peroxynitrite.
This selectivity and stability mean that ergothioneine can persist in tissues for extended periods, providing sustained antioxidant protection rather than the brief burst of activity seen with many dietary antioxidants.
Mitochondrial Protection
Ergothioneine accumulates in mitochondria, the cellular organelles responsible for energy production and a major source of endogenous ROS. By scavenging mitochondrial free radicals and chelating iron within the organelle, ergothioneine may help preserve mitochondrial function during aging — a process central to many theories of biological aging.
Preclinical studies have shown that ergothioneine protects mitochondrial DNA from oxidative damage and maintains membrane potential under stress conditions. This mitochondrial-targeted activity distinguishes it from many antioxidant supplements that don't efficiently reach mitochondria.
Anti-Inflammatory Pathways
Beyond direct antioxidant activity, ergothioneine modulates inflammatory signaling. Cell-based and animal studies have demonstrated that it can:
- Inhibit NF-κB activation, a master regulator of inflammatory gene expression
- Reduce production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Attenuate inflammatory damage in models of neuroinflammation, liver injury, and lung damage
The anti-inflammatory effects appear to be partly independent of its antioxidant activity, suggesting multiple modes of action.
Cytoprotection
Ergothioneine has demonstrated protective effects against various forms of cellular stress in laboratory models, including UV radiation damage, heavy metal toxicity, and ischemia-reperfusion injury. It also appears to inhibit certain forms of programmed cell death (ferroptosis and pyroptosis) that are driven by iron-dependent oxidative damage.
Ergothioneine Benefits: What the Research Shows
Cognitive Function — The 2025 RCT
The most significant clinical evidence for ergothioneine supplementation comes from a randomized, double-blind, placebo-controlled trial published by Zajac et al. in 2025. This study enrolled 147 healthy adults aged 50–75 and assigned them to receive either 25 mg of ergothioneine or placebo daily for 16 weeks [1].
The results were noteworthy:
- Memory improvement. The ergothioneine group showed statistically significant improvements in episodic memory tasks compared to placebo, with moderate effect sizes.
- Sleep quality. Participants taking ergothioneine reported improved subjective sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI).
- Processing speed. There were trends toward improved processing speed, though these did not reach statistical significance.
This trial is important because it's a properly designed RCT with a reasonable sample size, testing a specific dose over a meaningful duration. While a single trial doesn't establish definitive proof, it provides the kind of evidence that many supplements in the longevity space lack entirely.
Longevity and Aging Biomarkers
Epidemiological research has consistently linked higher blood levels of ergothioneine with markers of healthy aging:
- A large Singaporean cohort study found that higher plasma ergothioneine levels were associated with reduced risk of cardiovascular mortality, cognitive decline, and frailty over a 10+ year follow-up period.
- Swedish population data showed that plasma ergothioneine declines with age and that lower levels correlate with increased markers of oxidative stress and inflammation.
These observational findings align with the mechanistic data but cannot prove causation. People who eat more mushrooms may differ from non-consumers in many health-relevant ways.
Neuroprotection
The brain is particularly vulnerable to oxidative stress due to its high metabolic rate, abundant polyunsaturated fatty acids, and relatively modest antioxidant defenses. Ergothioneine's ability to cross the blood-brain barrier via OCTN1 makes it a candidate for neuroprotection.
Preclinical studies have shown protective effects in models of:
- Parkinson's disease (protecting dopaminergic neurons from oxidative damage)
- Alzheimer's disease (reducing amyloid-beta-induced toxicity)
- Traumatic brain injury
- Age-related cognitive decline
The 2025 Zajac RCT provides the first human clinical evidence supporting the neuroprotective hypothesis, though the participants were healthy adults rather than patients with neurodegenerative disease.
Cardiovascular Health
Ergothioneine's antioxidant and anti-inflammatory properties are relevant to cardiovascular health, given that oxidative stress and inflammation are central drivers of atherosclerosis. Animal studies have shown reduced arterial plaque formation and improved endothelial function with ergothioneine supplementation. Human cardiovascular data is limited to observational associations.
Eye Health
Ergothioneine concentrates in the lens and retina of the eye, suggesting a protective role against age-related eye diseases driven by oxidative damage (cataracts, macular degeneration). This is a biologically plausible but clinically unproven benefit as of 2026.
Dosage and How to Take Ergothioneine
The clinically tested dose in the Zajac RCT was 25 mg per day — this is the strongest evidence-based dose recommendation available.
Supplement products typically provide 5–25 mg per serving, with 5 mg and 25 mg being the most common options.
Dietary sources:
- King oyster mushrooms: ~2.5 mg per 100g (cooked)
- Maitake mushrooms: ~1.4 mg per 100g
- Shiitake mushrooms: ~1.1 mg per 100g
- Oyster mushrooms: ~0.8 mg per 100g
- Tempeh: ~0.3 mg per 100g
Reaching 25 mg daily from diet alone would require eating large quantities of mushrooms, which is feasible for mushroom enthusiasts but impractical for most people.
Timing: No specific time-of-day recommendation exists. Ergothioneine is water-soluble and can be taken with or without food, though absorption with food has not been formally compared to fasted administration.
Stacking considerations: Ergothioneine is sometimes combined with other antioxidants or longevity-oriented supplements (glutathione, NAC, CoQ10). These combinations are theoretically reasonable given non-overlapping mechanisms, but specific combination studies are lacking.
Safety and Side Effects
Ergothioneine has an excellent safety profile based on available data:
- It has received FDA GRAS status for use in food and beverages
- The 16-week Zajac RCT reported no significant adverse events at 25 mg/day [1]
- Toxicological studies in animals have shown no adverse effects at doses many times higher than human supplemental doses
- As a naturally occurring food component consumed by humans throughout evolutionary history, there is inherent safety context
No significant drug interactions have been reported. Theoretically, because ergothioneine is transported by OCTN1, other substrates of this transporter (certain cationic drugs) could compete for absorption, but this has not been shown to be clinically relevant.
Populations without sufficient safety data:
- Pregnant or breastfeeding women
- Children
- Individuals on immunosuppressive therapy (given anti-inflammatory effects)
How Ergothioneine Compares to Other Antioxidant Supplements
The antioxidant supplement market is crowded and often disappointing — large clinical trials of vitamin C, vitamin E, and beta-carotene have generally failed to show the benefits predicted by observational data and preclinical studies. Ergothioneine has several features that distinguish it from these predecessors:
1. Dedicated transporter. The body actively absorbs and retains ergothioneine, unlike most dietary antioxidants that are poorly absorbed or rapidly excreted.
2. Stability. Ergothioneine doesn't auto-oxidize or become pro-oxidant at high concentrations, a problem documented with vitamin C and vitamin E.
3. Tissue specificity. Accumulation in mitochondria, brain, and other high-stress tissues provides targeted rather than diffuse activity.
4. Clinical trial support. The 2025 Zajac RCT provides the kind of human evidence that many popular antioxidant supplements lack.
That said, one positive RCT does not make ergothioneine a proven longevity intervention. Independent replication in different populations and settings is needed.
Limitations of the Evidence
- Single major RCT. The Zajac 2025 trial is encouraging but needs replication. One trial, no matter how well-designed, is not sufficient to establish clinical practice.
- Healthy participants. The RCT studied healthy older adults. Whether ergothioneine benefits extend to people with existing cognitive impairment or chronic diseases is unknown.
- Short duration. Sixteen weeks is useful for detecting early biomarker changes but insufficient for evaluating long-term health outcomes like dementia incidence or mortality.
- Biomarker vs. clinical outcomes. Most benefits beyond the RCT are based on epidemiological associations and preclinical data, not hard clinical endpoints.
The Verdict
Ergothioneine stands out in the crowded antioxidant and longevity supplement space for several legitimate reasons: a dedicated human transporter suggesting biological importance, unique and stable antioxidant chemistry, mitochondrial and brain accumulation, and — crucially — actual RCT data showing cognitive and sleep benefits.
The 2025 Zajac trial moves ergothioneine from "interesting molecule" to "evidence-supported supplement," though the evidence remains early-stage. It needs independent replication and longer-term studies before it can be recommended with high confidence.
Who might benefit most:
- Adults over 50 interested in cognitive health maintenance
- People with low mushroom intake (and therefore likely low dietary ergothioneine)
- Those seeking antioxidant support with mechanistic credibility beyond generic "free radical scavenging"
The bottom line: Ergothioneine is one of the more scientifically grounded options in the longevity supplement category. At 5–25 mg per day with a clean safety profile, the risk–benefit calculus is favorable for those willing to act on emerging (but not yet definitive) evidence.